ABT licenses prostate-cancer biomarkers from Stanford University: I have great hope that this will have big ramifications for NGNM because ABT owns 10% of us and this is what we all were looking for when the deal was signed!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.